

Khang-Li Looi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/856400/publications.pdf>

Version: 2024-02-01

19
papers

210
citations

1163117

8
h-index

996975

15
g-index

19
all docs

19
docs citations

19
times ranked

363
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Ten-year trends in cardiac implantable electronic devices in New Zealand: a national data linkage study (<sc>ANZACS&QI</sc> 51). Internal Medicine Journal, 2022, 52, 614-622. | 0.8 | 3 |
| 2 | Regional variation in cardiac implantable electronic device implants trends in New Zealand over the past decade (<sc>ANZACS&QI</sc> 54). Internal Medicine Journal, 2022, 52, 1035-1047. | 0.8 | 2 |
| 3 | Implantable cardioverter defibrillator and cardiac resynchronization therapy use in New Zealand (ANZACS&QI 33). Journal of Arrhythmia, 2020, 36, 153-163. | 1.2 | 6 |
| 4 | Outcomes of patients with heart failure after primary prevention ICD unit generator replacement. Heart Asia, 2019, 11, e011162. | 1.1 | 3 |
| 5 | Utilization of cardiac resynchronization therapy in patients with heart failure in the Northern Region of New Zealand. Journal of Arrhythmia, 2019, 35, 52-60. | 1.2 | 3 |
| 6 | Impact of cardiac resynchronisation therapy on burden of hospitalisations and survival: a retrospective observational study in the Northern Region of New Zealand. BMJ Open, 2019, 9, e025634. | 1.9 | 2 |
| 7 | Gender differences in the use of primary prevention ICDs in New Zealand patients with heart failure. Heart Asia, 2018, 10, e010985. | 1.1 | 8 |
| 8 | Long-term outcomes of heart failure patients who received primary prevention implantable cardioverter-defibrillator: An observational study. Journal of Arrhythmia, 2018, 34, 46-54. | 1.2 | 8 |
| 9 | LV epicardial lead placement at time of cardiac surgery: useful for some-but not all. New Zealand Medical Journal, 2018, 131, 45-49. | 0.5 | 5 |
| 10 | Sex-specific outcomes with addition of defibrillation to resynchronisation therapy in patients with heart failure. Heart, 2017, 103, 753-760. | 2.9 | 21 |
| 11 | Prophylactic implantable cardioverter defibrillator in heart failure: the growing evidence for all or Primum non nocere for some?. Heart Failure Reviews, 2017, 22, 305-316. | 3.9 | 2 |
| 12 | Adding Defibrillation Therapy to Cardiac Resynchronization on the Basis of the Myocardial Substrate. Journal of the American College of Cardiology, 2017, 69, 1669-1678. | 2.8 | 56 |
| 13 | S pneumoniae purulent pericarditis in the setting of community-acquired pneumonia. New Zealand Medical Journal, 2017, 130, 80-85. | 0.5 | 0 |
| 14 | Applicability of a risk score for prediction of the long-term benefit of the implantable cardioverter defibrillator in patients receiving cardiac resynchronization therapy. Europace, 2016, 18, 1187-1193. | 1.7 | 25 |
| 15 | Adherence to the current guidelines for bradycardic pacing in the octogenarian and nonagenarian populations. New Zealand Medical Journal, 2016, 129, 33-40. | 0.5 | 0 |
| 16 | Ventricular arrhythmia storm in the era of implantable cardioverter-defibrillator. Postgraduate Medical Journal, 2015, 91, 519-526. | 1.8 | 11 |
| 17 | Cardiac resynchronisation therapy: pacemaker versus internal cardioverter-defibrillator in patients with impaired left ventricular function. Heart, 2014, 100, 794-799. | 2.9 | 27 |
| 18 | Conscious sedation and analgesia use in cardiac device implantation. International Journal of Cardiology, 2013, 168, 561-563. | 1.7 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Long-term outcomes (>2Âyears) of atrial fibrillation ablation using a multi-electrode ablation catheter in patients with paroxysmal atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2013, 36, 61-69. | 1.3 | 16 |